Work

46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.01.055

Institution: Arcus Biosciences (United States)

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4220802499

FWCI: 0.357

Cites:

Cited by: 6

Related to: 10